Overview

Botulinum Toxins Intralesional Injection for Scar Pain

Status:
Unknown status

Trial end date:
2019-06-30

Target enrollment:
0

Participant gender:
All

Summary

Botulinum toxins has been approved by the FDA to treat chronic migraine. Botox had been shown to inhibiting the release of inflammatory mediators and peripheral neurotransmitters from sensory nerve to treat neuropathic pain. In the clinical practice, botox indeed effect in scar pain. However, investigators need well controlled study to prove this finding and assess the improvement of scar appearance.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Kaohsiung Medical University

Treatments:

abobotulinumtoxinA
Botulinum Toxins
Botulinum Toxins, Type A
Lidocaine
Triamcinolone
Triamcinolone Acetonide
Triamcinolone diacetate
Triamcinolone hexacetonide

Criteria

Inclusion Criteria:

1. Patients have visible hypertrophic scars or keloids over three months after trauma or
surgery.

2. Patients have symptoms of pain, itching or erythema.

Exclusion Criteria:

1. Patients had either Botulinum toxin type A or Triamcinolone intralesional before in
the same scar

2. The scar size is larger than 10 cm2

3. Immunocompromised status

4. Systemic infection status

5. Allergic to Botulinum toxin type A or steroids